Cue Biopharma, Inc. 8-K

What Happened
Cue Biopharma, Inc. (CUE) filed an 8-K reporting that it has filed a Certificate of Amendment to implement a 1-for-30 reverse stock split of its common stock, effective 5:00 p.m. Eastern Time on April 23, 2026. The company says the Reverse Stock Split is intended to help it comply with the Nasdaq Capital Market minimum bid price requirement. The Certificate of Amendment was filed with the Delaware Secretary of State.

Key Details

• Reverse split ratio: 1-for-30 (every 30 issued and outstanding shares automatically combined into one).
• Effective time/date: 5:00 p.m. ET on April 23, 2026; common stock expected to trade on a post-split basis at market open on April 24, 2026 under the existing ticker CUE.
• Fractional shares: No fractional shares will be issued — holders entitled to fractions will receive a cash payment in lieu of fractional shares.
• Securities adjustments: Outstanding stock options, warrants and available shares under equity incentive plans will be proportionally adjusted (fewer shares exercisable, higher exercise prices) per plan/security terms.
• Administrative: The reverse split does not change the number of authorized shares or the $0.001 par value; new CUSIP after the split: 22978P205.

Why It Matters
The reverse split reduces the number of outstanding shares and increases the per-share price, which is intended to bring CUE into compliance with Nasdaq’s minimum bid price rule and avoid potential delisting. For shareholders, this means your share count will be reduced (with cash paid for any fractional shares) and option/warrant strike and share counts will be adjusted proportionally. These are mechanical corporate actions — they don’t change the company’s market value directly but can affect trading liquidity, per-share metrics, and investor perception.